Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics.
COVID-19
dosage regimens
drug monitoring
hydroxychloroquine
population pharmacokinetic modeling
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
31 12 2020
31 12 2020
Historique:
received:
10
04
2020
accepted:
07
05
2020
pubmed:
12
5
2020
medline:
7
1
2021
entrez:
12
5
2020
Statut:
ppublish
Résumé
Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 days, and concentrations were compared with simulated kinetic profiles. Hydroxychloroquine exposure is low and cannot be predicted by other populations.
Identifiants
pubmed: 32392332
pii: 5835847
doi: 10.1093/cid/ciaa558
pmc: PMC7239205
doi:
Substances chimiques
Antiviral Agents
0
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2962-2964Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.